ImmunityBio, Inc. — Director's Dealing 2021

Jan 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NantKwest, Inc. (NK)
CIK: 0001326110
Period of Report: 2021-01-12

Reporting Person: Nelson Sonja (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-12	Common Stock	M	11364	$3.07	Acquired	31774	Direct
2021-01-12	Common Stock	S	16364	$15.00	Disposed	15410	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-12	Stock Option (right to buy)	$3.07	M	11364	Disposed	2028-08-27	Common Stock (11364)	Direct

Footnotes

F1: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 4, 2020.

F2: Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022.